IRINA LATTANZI MD
Prescription History 1700945441
Internal Medicine - Pulmonary Disease in Woodland Hills, CA

NPI Status: Active since December 08, 2006

Contact Information

5601 DE SOTO AVE
WOODLAND HILLS, CA
ZIP 91367
Phone: (818) 719-2000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for IRINA LATTANZI MD, an active Pulmonary Disease specialist practicing in Woodland Hills, CA. Our medical registry currently tracks 20 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,171 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 233 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 233
30-Day Fills 333.3
Days Supply 9,850
CA State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills62.5
Peer Average Days Supply1,577
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 339.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,925.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.43

State Avg Cost Per Claim

$42.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 33.2
Days Supply 996
CA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills138.0
Peer Average Days Supply4,109
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $124.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.36

State Avg Cost Per Claim

$12.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Alvesco

Generic Formulation: CiclesonideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 59
30-Day Fills 145.0
Days Supply 4,350
CA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills68.7
Peer Average Days Supply2,045
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.9% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,011.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$169.69

State Avg Cost Per Claim

$141.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ciclesonide is used to prevent and reduce the symptoms (wheezing and shortness of breath) caused by asthma. Controlling asthma symptoms may decrease time lost from work or school. This medication belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. This medication must be taken regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed. Keep track of how often you need to use your quick-relief inhaler, and tell your doctor. If your quick-relief inhaler does not seem to work as well, if you need to use more than usual of your quick-relief inhaler for 2 or more days in a row, or if you need to use more than one full canister of your quick-relief inhaler over a 2-month period, seek immediate medical attention.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 15
30-Day Fills 20.3
Days Supply 575
CA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills63.3
Peer Average Days Supply1,830
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $300.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.05

State Avg Cost Per Claim

$42.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 88
30-Day Fills 149.0
Days Supply 3,293
CA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.6
Peer Average Days Supply270
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 131.6% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,069.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.52

State Avg Cost Per Claim

$7.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 25.0
Days Supply 750
CA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills45.4
Peer Average Days Supply1,348
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,864.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$704.62

State Avg Cost Per Claim

$509.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breyna

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 26.3
Days Supply 788
CA State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$186.52

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 22
30-Day Fills 60.2
Days Supply 1,807
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills24.9
Peer Average Days Supply737
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.4% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,014.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,046.11

State Avg Cost Per Claim

$488.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Levalbuterol Tartrate Hfa

Generic Formulation: Levalbuterol TartrateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.7
Peer Average Days Supply526
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $818.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$68.24

State Avg Cost Per Claim

$70.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levalbuterol is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). It is a quick-relief drug. Levalbuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This drug is not approved for use in children younger than 4 years due to increased risk of side effects (such as unusual fast breathing, worsening asthma). Ask your doctor or pharmacist for details.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 92
30-Day Fills 194.6
Days Supply 5,840
CA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills106.0
Peer Average Days Supply3,154
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 91.7% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $875.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.52

State Avg Cost Per Claim

$17.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.9
Peer Average Days Supply558
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,387.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$489.75

State Avg Cost Per Claim

$3,941.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 53
30-Day Fills 78.6
Days Supply 1,453
CA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,075
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.5% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $634.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.96

State Avg Cost Per Claim

$8.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Rifampin

Generic Formulation: RifampinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 19.6
Days Supply 588
CA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply772
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $740.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.94

State Avg Cost Per Claim

$76.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Roflumilast

Generic Formulation: RoflumilastSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 26.0
Days Supply 780
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills31.3
Peer Average Days Supply934
Conservative Utilization

This provider writes prescriptions for this formulation 30.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,076.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$76.86

State Avg Cost Per Claim

$352.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 134
30-Day Fills 223.0
Days Supply 6,690
CA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills50.8
Peer Average Days Supply1,521
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 318.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $64,808.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$483.65

State Avg Cost Per Claim

$561.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 136
30-Day Fills 262.0
Days Supply 7,860
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills44.4
Peer Average Days Supply1,330
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 385.7% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $79,482.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$584.43

State Avg Cost Per Claim

$637.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 126
30-Day Fills 192.0
Days Supply 5,738
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills42.5
Peer Average Days Supply1,272
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 320.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $51,102.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$405.57

State Avg Cost Per Claim

$518.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.5
Days Supply 375
CA State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills68.5
Peer Average Days Supply2,048
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,500.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$708.37

State Avg Cost Per Claim

$825.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 20
30-Day Fills 30.0
Days Supply 804
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills34.7
Peer Average Days Supply841
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,100.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$105.03

State Avg Cost Per Claim

$73.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 89
30-Day Fills 209.7
Days Supply 6,290
CA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills56.1
Peer Average Days Supply1,681
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 217.9% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,711.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$232.71

State Avg Cost Per Claim

$246.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like IRINA LATTANZI MD provides transparency into local medical care patterns within Woodland Hills, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.